Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study

Corrado Pelaia,1 Anna Ferrante Bannera,1 Fioramante Lello Rotundo,1 Francesco Giuseppe Tropea,1 Giuseppe Armentaro,2 Angelantonio Maglio,3 Angela Sciacqua,2 Alessandro Vatrella,3 Girolamo Pelaia1 1Department of Health Sciences, University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 2Department of...

Full description

Bibliographic Details
Main Authors: Pelaia C, Ferrante Bannera A, Rotundo FL, Tropea FG, Armentaro G, Maglio A, Sciacqua A, Vatrella A, Pelaia G
Format: Article
Language:English
Published: Dove Medical Press 2023-05-01
Series:International Journal of COPD
Subjects:
Online Access:https://www.dovepress.com/clinical-and-functional-effects-of-inhaled-dual-therapy-umeclidiniumvi-peer-reviewed-fulltext-article-COPD
_version_ 1797817661140238336
author Pelaia C
Ferrante Bannera A
Rotundo FL
Tropea FG
Armentaro G
Maglio A
Sciacqua A
Vatrella A
Pelaia G
author_facet Pelaia C
Ferrante Bannera A
Rotundo FL
Tropea FG
Armentaro G
Maglio A
Sciacqua A
Vatrella A
Pelaia G
author_sort Pelaia C
collection DOAJ
description Corrado Pelaia,1 Anna Ferrante Bannera,1 Fioramante Lello Rotundo,1 Francesco Giuseppe Tropea,1 Giuseppe Armentaro,2 Angelantonio Maglio,3 Angela Sciacqua,2 Alessandro Vatrella,3 Girolamo Pelaia1 1Department of Health Sciences, University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 2Department of Medical and Surgical Sciences, University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 3Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, ItalyCorrespondence: Corrado Pelaia, Campus Universitario “S. Venuta”, Viale Europa – Località Germaneto, Catanzaro, 88100, Italy, Tel +39 0961 3647007, Fax +39 0961 3647193, Email pelaia.corrado@gmail.comBackground: The pharmacological association umeclidinium/vilanterol (UMEC/VI) allows to implement a very effective dual bronchodilation in chronic obstructive pulmonary disease (COPD), thus optimizing bronchodilating therapy.Methods: The main purpose of our real-world observational study was to evaluate in COPD patients the effects of UMEC/VI on lung function and respiratory symptoms. Functional and clinical parameters were assessed at baseline, and after 52 weeks of treatment with this combined double inhaled therapy.Results: We enrolled 110 subjects suffering from COPD. A 12-month UMEC/VI treatment induced significant improvements in total lung capacity (TLC) (p < 0.05), and residual volume (RV) (p < 0.0001). Pulmonary deflation was paralleled by significant increases of forced expiratory volume in one second (FEV1) (p < 0.0001), forced vital capacity (FVC) (p < 0.01), forced expiratory flow between 25% and 75% of FVC (FEF25– 75) (p < 0.0001) and diffusion capacity of the lung (DLCOcSB) (p < 0.05). In addition, in the same period, we also observed significant reductions of airway resistance including total resistance (Rtot) (p < 0.0001) and specific effective resistance (sReff) (p < 0.0001). Other improvements were detected with regard to modified British Medical Research Council (mMRC) questionnaire score (p < 0.0001), COPD Assessment Test (CAT) score (p < 0.0001), and COPD exacerbation rate (p < 0.0001). In particular, the reported changes of mMRC/CAT scores and COPD exacerbation numbers were significantly correlated with UMEC/VI–induced modifications of TLC, RV, FVC and FEV1.Conclusion: In conclusion, our study corroborates in a real-life context the effectiveness of UMEC/VI in COPD treatment. Indeed, our broad investigational strategy has allowed to better characterize the functional mechanisms underpinning the therapeutic properties of UMEC/VI association.Keywords: COPD, dual inhaled therapy, lung function, airway resistance, exacerbations
first_indexed 2024-03-13T08:56:46Z
format Article
id doaj.art-ce1726c94f364b91a8d62a217b0be5c3
institution Directory Open Access Journal
issn 1178-2005
language English
last_indexed 2024-03-13T08:56:46Z
publishDate 2023-05-01
publisher Dove Medical Press
record_format Article
series International Journal of COPD
spelling doaj.art-ce1726c94f364b91a8d62a217b0be5c32023-05-28T19:04:57ZengDove Medical PressInternational Journal of COPD1178-20052023-05-01Volume 18995100283998Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life StudyPelaia CFerrante Bannera ARotundo FLTropea FGArmentaro GMaglio ASciacqua AVatrella APelaia GCorrado Pelaia,1 Anna Ferrante Bannera,1 Fioramante Lello Rotundo,1 Francesco Giuseppe Tropea,1 Giuseppe Armentaro,2 Angelantonio Maglio,3 Angela Sciacqua,2 Alessandro Vatrella,3 Girolamo Pelaia1 1Department of Health Sciences, University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 2Department of Medical and Surgical Sciences, University “Magna Græcia” of Catanzaro, Catanzaro, Italy; 3Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, ItalyCorrespondence: Corrado Pelaia, Campus Universitario “S. Venuta”, Viale Europa – Località Germaneto, Catanzaro, 88100, Italy, Tel +39 0961 3647007, Fax +39 0961 3647193, Email pelaia.corrado@gmail.comBackground: The pharmacological association umeclidinium/vilanterol (UMEC/VI) allows to implement a very effective dual bronchodilation in chronic obstructive pulmonary disease (COPD), thus optimizing bronchodilating therapy.Methods: The main purpose of our real-world observational study was to evaluate in COPD patients the effects of UMEC/VI on lung function and respiratory symptoms. Functional and clinical parameters were assessed at baseline, and after 52 weeks of treatment with this combined double inhaled therapy.Results: We enrolled 110 subjects suffering from COPD. A 12-month UMEC/VI treatment induced significant improvements in total lung capacity (TLC) (p < 0.05), and residual volume (RV) (p < 0.0001). Pulmonary deflation was paralleled by significant increases of forced expiratory volume in one second (FEV1) (p < 0.0001), forced vital capacity (FVC) (p < 0.01), forced expiratory flow between 25% and 75% of FVC (FEF25– 75) (p < 0.0001) and diffusion capacity of the lung (DLCOcSB) (p < 0.05). In addition, in the same period, we also observed significant reductions of airway resistance including total resistance (Rtot) (p < 0.0001) and specific effective resistance (sReff) (p < 0.0001). Other improvements were detected with regard to modified British Medical Research Council (mMRC) questionnaire score (p < 0.0001), COPD Assessment Test (CAT) score (p < 0.0001), and COPD exacerbation rate (p < 0.0001). In particular, the reported changes of mMRC/CAT scores and COPD exacerbation numbers were significantly correlated with UMEC/VI–induced modifications of TLC, RV, FVC and FEV1.Conclusion: In conclusion, our study corroborates in a real-life context the effectiveness of UMEC/VI in COPD treatment. Indeed, our broad investigational strategy has allowed to better characterize the functional mechanisms underpinning the therapeutic properties of UMEC/VI association.Keywords: COPD, dual inhaled therapy, lung function, airway resistance, exacerbationshttps://www.dovepress.com/clinical-and-functional-effects-of-inhaled-dual-therapy-umeclidiniumvi-peer-reviewed-fulltext-article-COPDcopddual inhaled therapylung functionairway resistanceexacerbations.
spellingShingle Pelaia C
Ferrante Bannera A
Rotundo FL
Tropea FG
Armentaro G
Maglio A
Sciacqua A
Vatrella A
Pelaia G
Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
International Journal of COPD
copd
dual inhaled therapy
lung function
airway resistance
exacerbations.
title Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
title_full Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
title_fullStr Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
title_full_unstemmed Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
title_short Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
title_sort clinical and functional effects of inhaled dual therapy umeclidinium vilanterol in patients with chronic obstructive pulmonary disease a real life study
topic copd
dual inhaled therapy
lung function
airway resistance
exacerbations.
url https://www.dovepress.com/clinical-and-functional-effects-of-inhaled-dual-therapy-umeclidiniumvi-peer-reviewed-fulltext-article-COPD
work_keys_str_mv AT pelaiac clinicalandfunctionaleffectsofinhaleddualtherapyumeclidiniumvilanterolinpatientswithchronicobstructivepulmonarydiseaseareallifestudy
AT ferrantebanneraa clinicalandfunctionaleffectsofinhaleddualtherapyumeclidiniumvilanterolinpatientswithchronicobstructivepulmonarydiseaseareallifestudy
AT rotundofl clinicalandfunctionaleffectsofinhaleddualtherapyumeclidiniumvilanterolinpatientswithchronicobstructivepulmonarydiseaseareallifestudy
AT tropeafg clinicalandfunctionaleffectsofinhaleddualtherapyumeclidiniumvilanterolinpatientswithchronicobstructivepulmonarydiseaseareallifestudy
AT armentarog clinicalandfunctionaleffectsofinhaleddualtherapyumeclidiniumvilanterolinpatientswithchronicobstructivepulmonarydiseaseareallifestudy
AT maglioa clinicalandfunctionaleffectsofinhaleddualtherapyumeclidiniumvilanterolinpatientswithchronicobstructivepulmonarydiseaseareallifestudy
AT sciacquaa clinicalandfunctionaleffectsofinhaleddualtherapyumeclidiniumvilanterolinpatientswithchronicobstructivepulmonarydiseaseareallifestudy
AT vatrellaa clinicalandfunctionaleffectsofinhaleddualtherapyumeclidiniumvilanterolinpatientswithchronicobstructivepulmonarydiseaseareallifestudy
AT pelaiag clinicalandfunctionaleffectsofinhaleddualtherapyumeclidiniumvilanterolinpatientswithchronicobstructivepulmonarydiseaseareallifestudy